Infusions and Special Medicines Board Expert Panel Working Group – Call for applications

At the national Quality Assurance and Technical Services symposium on the 9th of November we announced the launch of an Expert Panel to provide the governance and assurance for the product standardisation agenda.

This group will consist of professionals from a wide range of backgrounds, and we’d like to encourage as many people as possible to apply. It will initially meet to agree terms of reference and establish a work pattern. Members will then review and comment on the specifications, prompting a review of the documents before they are published for a public consultation. Once the consultation ends and any final alterations have been made the members will review once more before the official publication of the specifications.

This initial phase is focusing on chemotherapy agents and we will be looking for clinical specialists in that area. These specialists will rotate in and out of the group as we expand the project to cover other classes of medicines.

Once all existing products have been completed the group will only need to meet and provide this function on an ad-hoc basis as new medicines are marketed and dose banding tables established.

Details of the roles and the panel can be found here:FutureNHS Collaboration Platform – FutureNHS Collaboration Platform  and in the document available at this link https://www.bopa.org.uk/resources/expression-of-interest-slwg-infusions-and-special-medicines-expert-panel-standardisation/

Please circulate to your Trust teams, the deadline for applications is 23:59 25th Nov 2022 and should be done via this Form

Thanks, in advance,

Matt Greening

Senior Pharmacy Professional Advisor – Infusions and Special Medicines Programme

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article